Celularity (CELU)
NASDAQ:CELU
CELU Stock Chart & Stats
$1.25
-$0.06(-2.69%)
At close: 4:00 PM EST
$1.25
-$0.06(-2.69%)
Day’s Range― - ―
52-Week Range$1.01 - $4.35
Previous Close$2.13
Volume115.00K
Average Volume (3M)206.82K
Market Cap
$36.91M
Enterprise Value$97.91M
Total Cash (Recent Filing)$120.00K
Total Debt (Recent Filing)$66.76M
Price to Earnings (P/E)―
Beta3.29
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,837,788
10 Day Avg. Volume277,262
30 Day Avg. Volume206,824
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)5.15
Price to Sales (P/S)0.84
P/FCF Ratio-6.94
Enterprise Value/Market Cap2.65
Enterprise Value/Revenue2.41
Enterprise Value/Gross Profit4.37
Enterprise Value/Ebitda-1.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Bulls Say, Bears Say
Bulls Say
Solid Gross Margin (~55%)A sustained ~55% gross margin indicates the core therapeutic products have favorable unit economics. Over the medium term this supports scalable profitability if SG&A and R&D growth are controlled, and it strengthens the case for margin recovery as revenues stabilize.
Proprietary Placental-derived PlatformA unique, platform-driven approach creates durable competitive advantages: platform extensibility across oncology, degenerative diseases and longevity enables multiple indications, partnership opportunities, and potential recurring revenue streams from licensing or co-development.
Improved Cash Burn Vs Prior YearsMaterial reduction in cash burn versus earlier years shows progress on cost discipline and raises the runway profile. While still negative, lower burn reduces near-term financing frequency and gives management more time to execute commercialization or restructuring initiatives.
Bears Say
Deep Unprofitability And Falling RevenueSevere losses and shrinking revenue impair the company’s ability to self-fund growth and extend runway. Persistently negative margins force reliance on external capital, increasing dilution risk and constraining long-term investments in R&D and commercial scale-up.
Weakened Balance Sheet; Negative EquityNegative equity and sizable debt reduce financial flexibility, elevate refinancing risk, and may trigger restrictive covenants. This structural leverage constraint makes funding future trials or commercialization more costly and increases the likelihood of dilutive financings.
Dilutive, Investor-favorable Financing And Governance RightsWhile the package improves near-term liquidity, investor-favorable terms and governance visibility can limit strategic flexibility, increase potential dilution via conversion/warrants, and prioritize investor upside over long-term shareholder value during future financings.
Celularity News
CELU FAQ
What was Celularity’s price range in the past 12 months?
Celularity lowest stock price was $1.01 and its highest was $4.35 in the past 12 months.
What is Celularity’s market cap?
Celularity’s market cap is $36.91M.
When is Celularity’s upcoming earnings report date?
Celularity’s upcoming earnings report date is Apr 01, 2027 which is in 351 days.
How were Celularity’s earnings last quarter?
Currently, no data Available
Is Celularity overvalued?
According to Wall Street analysts Celularity’s price is currently Overvalued.
Does Celularity pay dividends?
Celularity does not currently pay dividends.
What is Celularity’s EPS estimate?
Celularity’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celularity have?
Celularity has 28,837,788 shares outstanding.
What happened to Celularity’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Celularity?
Currently, no hedge funds are holding shares in CELU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celularity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Technical Analysis
Ownership Overview
26.84% Insiders
2.48% Mutual Funds
3.29% Other Institutional Investors
65.19% Public Companies and
Individual Investors